Download A4Medicine Mobile App
Empower Your RCGP AKT Journey: Master the MCQs with Us! 🚀
Empagliflozin, a medication under the brand Jardiance by Boehringer Ingelheim, is an important treatment option for adults with symptomatic chronic heart failure. Recognized for its effectiveness in managing heart failure with both preserved or mildly reduced ejection fraction and reduced ejection fraction, it has become a key part of heart failure therapy. The medication's clinical trials demonstrate its ability to reduce the risk of cardiovascular death and hospitalization for heart failure, making it a valuable choice for patients and healthcare providers.
| Recommendation | Rationale |
|---|---|
| Empagliflozin for Chronic Heart Failure | Approved for symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults. |
| Choice Between Empagliflozin and Dapagliflozin | Clinician and patient should choose the least expensive option after considering advantages, disadvantages, and costs. |
| Standard Care and Addition of Empagliflozin | Standard care typically includes loop diuretics. Empagliflozin, like dapagliflozin, can be added to this regimen. |
| Evidence of Clinical Efficacy | Clinical trial data shows empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure compared to placebo. |
| Comparison with Dapagliflozin | Indirect comparisons suggest similar clinical effectiveness and quality of life impact between empagliflozin and dapagliflozin. |
| Cost Comparison | Similar costs to dapagliflozin, making empagliflozin a recommended option. |
| Specialist Advice for Initiation... |
Try our Free Plan to get the full article.
